Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

Core Insights - Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for oncology, specifically for multiple solid tumor indications [3] - The company will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on February 11-12, 2026 [1] - Brian Sullivan, CEO and Co-founder of Celcuity, is scheduled for a fireside chat on February 11, 2026, at 9:30 a.m. ET, with a live webcast available [2] Company Overview - Celcuity's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTORC1/2 inhibitor that targets the PI3K/AKT/mTOR pathway [3] - The company has completed enrollment for the Phase 3 clinical trial VIKTORIA-1, which evaluates gedatolisib in combination with fulvestrant in patients with HR+/HER2- ABC, and has reported results for the PIK3CA wild-type cohort [3] - The ongoing Phase 3 clinical trial VIKTORIA-2 is assessing gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR+/HER2- ABC patients [3] - A Phase 1/2 clinical trial, CELC-G-201, is evaluating gedatolisib in combination with darolutamide for metastatic castration-resistant prostate cancer [3]